VCYCLE - Virtual Cycling Environments Trial (NCT04804202)
Overview
Mermaid diagram (expand to render)
VCYCLE (Virtual Cycling Environments) is a Phase 2 randomized controlled trial conducted at Rutgers University that evaluates the effects of immersive virtual reality (VR) cycling exercise on motor function, cognition, and quality of life in individuals with [Parkinson's disease](/diseases/parkinsons-disease). The study investigates whether combining VR environments with cycling provides enhanced neuroprotective benefits compared to traditional exercise alone.
Trial Summary
| Field | Details |
|-------|---------|
| NCT Number | NCT04804202 |
| Title | Virtual Cycling Environments (VCYCLE) Trial |
| Status | COMPLETED |
| Phase | Phase 2 |
| Sponsor | Rutgers, The State University of New Jersey |
| Intervention | Virtual reality-enhanced cycling exercise |
| Enrollment | 40 participants |
| Study Period | 2021-2023 |
| Duration | 12 weeks |
| Frequency | 3 sessions per week |
Background and Rationale
Exercise and Parkinson's Disease
Regular exercise has been established as a cornerstone of Parkinson's disease management, with robust evidence supporting its benefits across multiple domains[@exercise2021]. The therapeutic effects of exercise in PD extend beyond simple motor symptom improvement to potentially disease-modifying neuroprotective mechanisms[@urs2022].
Motor Benefits
- Improved motor function: Reduced Unified Parkinson's Disease Rating Scale (UPDRS) scores
- Enhanced gait: Increased gait velocity, stride length, and reduced freezing
- Better balance: Improved postural stability and reduced fall risk
- Reduced bradykinesia: Faster movement initiation and execution
Non-Motor Benefits
- Cognitive enhancement: Improved executive function and processing speed
- Mood improvement: Reduced depression and anxiety symptoms
- Sleep quality: Better sleep architecture and reduced insomnia
- Fatigue reduction: Improved energy levels and daily functioning
Neuroprotective Mechanisms
Exercise exerts neuroprotective effects through multiple biological pathways:
Brain-derived neurotrophic factor (BDNF): Exercise increases peripheral and central BDNF levels, promoting neuronal survival and plasticity[@shapkin2021]
Neuroinflammation reduction: Anti-inflammatory effects through modulation of microglia and cytokines
Mitochondrial function: Enhanced mitochondrial biogenesis and reduced oxidative stress
Alpha-synuclein modulation: Evidence suggests exercise may promote protein clearance pathways
Neurogenesis: Exercise stimulates hippocampal and subventricular zone neurogenesisVirtual Reality in Rehabilitation
Virtual reality technology offers unique advantages for exercise rehabilitation in neurological conditions[@shen2022]:
Engagement and Adherence
- Immersive environments increase exercise engagement and motivation
- Gamification elements transform exercise into enjoyable activities
- Biofeedback integration provides real-time performance information
- Reduced perceived exertion allows for higher exercise intensities
Dual-Task Training
VR can seamlessly incorporate cognitive challenges during physical activity:
- Attention demands: Divided attention tasks during walking/cycling
- Executive function: Planning and decision-making in virtual environments
- Memory tasks: Recall exercises integrated with movement
- Visuospatial processing: Navigation and spatial orientation tasks
Sensory Modulation
- Visual feedback: Enhanced proprioceptive input through virtual cues
- Auditory cues: Rhythmic auditory stimulation for movement timing
- Sensory substitution: Alternative sensory channels for motor learning
Safety and Control
- Controlled challenges: Gradual difficulty progression in safe environment
- Errorless learning: Reduced fall risk during training
- Standardized protocols: Consistent training conditions across sessions
Combined VR-Cycling Approach
The VCYCLE protocol combines multiple evidence-based therapeutic elements:
Aerobic exercise: Cycling provides consistent moderate-intensity exercise with low fall risk
Virtual environments: Immersive VR scenarios increase engagement and motivation
Dual-task paradigms: Cognitive challenges integrated with physical activity
Rhythmic auditory stimulation: Music and cues enhance movement timing
Progressive difficulty: Systematic increase in challenge over 12 weeksStudy Design
Trial Structure
| Parameter | Value |
|-----------|-------|
| Design | Randomized controlled trial |
| Allocation | 1:1 ratio |
| Arms | VR-cycling vs. standard cycling |
| Blinding | Single-blind (outcomes assessor) |
| Duration | 12 weeks |
| Sessions | 3x per week, 45-60 min/session |
| Assessments | Pre, mid, post, and 4-week follow-up |
Randomization and Blinding
Participants were randomly assigned to one of two groups using computer-generated randomization. The outcome assessors remained blinded to group assignment throughout the study period. Due to the nature of the intervention, participants and intervention staff could not be blinded.
Intervention Protocol
VR-Cycling Group
The virtual reality cycling intervention included:
Equipment setup
- Stationary recumbent bicycle with integrated sensors
- Head-mounted display (Oculus Quest or equivalent)
- Heart rate monitor for intensity tracking
- Resistance bands for upper body engagement
Virtual environments
- Scenic routes: Virtual cycling through forests, beaches, mountain trails
- Game-based challenges: Interactive obstacle avoidance, collection games
- Social environments: Virtual group cycling with avatars
- Customizable environments: User preference selection
Progression protocol
- Week 1-2: Familiarization, basic environments
- Week 3-6: Moderate difficulty, introduction of cognitive tasks
- Week 7-10: Advanced environments, complex dual-task challenges
- Week 11-12: Maintenance, individualized difficulty
Intensity monitoring
- Target heart rate: 50-70% heart rate reserve
- Rating of perceived exertion (RPE) scale
- Talk test for aerobic threshold
- Individualized adjustments based on fitness level
Standard Cycling Group
The control group received:
Stationary cycling using same bicycle equipment (without VR)
Standard exercise guidance from trained staff
Matching session duration and frequency
Heart rate monitoring for intensity control
Basic educational materials about exercise and PDOutcome Measures
Primary Endpoints
Motor function: MDS-UPDRS Part III (Movement Disorder Society Unified Parkinson's Disease Rating Scale, Motor Examination)
- Assessed by trained clinician
- Video recording for reliability verification
- Standardized administration protocol
Gait velocity: 10-meter walk test
- Timed over middle 10 meters
- Self-selected and fast-paced conditions
- Three trials averaged
Balance: Berg Balance Scale
- 14-item functional balance scale
- Scoring 0-56, higher = better
- Full assessment at each timepoint
Secondary Endpoints
Cognitive function
- MoCA (Montreal Cognitive Assessment): Global cognitive screening
- Trail Making Test A & B: Processing speed and executive function
- Digit Span: Working memory
Quality of life
- PDQ-39 (Parkinson's Disease Questionnaire-39): Disease-specific QoL
- SF-36: General health status
Mood assessment
- BDI-II (Beck Depression Inventory): Depression severity
- STAI (State-Trait Anxiety Inventory): Anxiety levels
Exercise adherence
- Session completion rate
- Duration achieved
- Intensity achieved
Exploratory Endpoints
- Brain imaging (subset): Structural MRI in consenting participants
- Biomarker analysis: BDNF, inflammatory markers
- Dual-task cost assessment: Gait parameters under cognitive load
Mechanism of Neuroprotection
Exercise-Induced Neuroprotection
The theoretical framework for exercise benefits in PD involves multiple complementary mechanisms[@urs2022]:
Neurotrophic Factor Enhancement
BDNF Signaling
Exercise upregulates brain-derived neurotrophic factor expression through:
- Muscle contraction-induced peripheral BDNF release
- Improved hippocampal and striatal BDNF signaling
- Enhanced TrkB receptor activation in dopaminergic neurons
- Synaptic plasticity promotion
Other Neurotrophins
- Glial cell line-derived neurotrophic factor (GDNF)
- Insulin-like growth factor-1 (IGF-1)
- Vascular endothelial growth factor (VEGF)
Anti-Inflammatory Effects
Exercise modulates neuroinflammation through:
- Reduced microglial activation
- Decreased pro-inflammatory cytokines (IL-1β, TNF-α)
- Increased anti-inflammatory markers (IL-10, TGF-β)
- Improved blood-brain barrier integrity
Mitochondrial Function
Aerobic exercise enhances mitochondrial health:
- Increased mitochondrial biogenesis (PGC-1α activation)
- Improved electron transport chain function
- Reduced mitochondrial DNA damage
- Enhanced mitophagy and quality control
Alpha-Synuclein Modulation
Evidence suggests exercise may affect protein homeostasis:
- Enhanced autophagy flux
- Reduced oligomeric species accumulation
- Improved proteasomal function
- Potential effects on exosome release
VR Enhancement Mechanisms
The addition of VR to cycling may augment exercise benefits through several mechanisms:
Increased Exercise Intensity
- Greater engagement leads to longer session duration
- Reduced perceived exertion allows higher intensities
- Game-based motivation increases effort
- Immersion provides distraction from fatigue
Additional Cognitive Challenge
VR environments require continuous:
- Visual processing and attention
- Spatial navigation and orientation
- Decision-making and planning
- Dual-task performance
This dual-task training may enhance:
- Frontal lobe function
- Executive network efficiency
- Automaticity of movement
Sensory Enhancement
VR provides additional sensory input:
- Rich visual feedback for movement
- Auditory cues for rhythm and timing
- Propriceptive enhancement through virtual body representation
- Multisensory integration training
Motivation and Adherence
The immersive nature of VR improves:
- Exercise enjoyment and satisfaction
- Intrinsic motivation
- Self-efficacy for exercise
- Long-term adherence potential
Results and Outcomes
Expected Findings
Based on prior literature, the VCYCLE trial was designed to test the hypothesis that VR-enhanced cycling produces greater improvements than standard cycling in:
Motor symptoms: Greater reduction in MDS-UPDRS Part III scores
Gait parameters: Larger improvements in velocity, stride length
Balance: Enhanced postural stability on Berg Balance Scale
Cognition: Superior improvements in executive function
Quality of life: Greater PDQ-39 score improvementsClinical Implications
If the VR-cycling approach demonstrates superiority, this would support:
Enhanced rehabilitation protocols: Integration of VR technology into PD rehabilitation
Dose-response optimization: Potential for greater benefit per unit time invested
Adherence improvement: More engaging interventions for long-term exercise
Home-based options: Possibility of VR cycling for remote rehabilitationLimitations and Considerations
- Sample size: Phase 2 trial with limited statistical power
- Generalizability: Single-site study may not represent all populations
- Technology barriers: VR may not be accessible to all patients
- Learning curve: VR technology may challenge some participants
- Long-term effects: Unknown if benefits persist beyond follow-up period
Detailed Statistical Analysis
Sample Size Considerations
The VCYCLE trial enrolled 40 participants (20 per arm) based on:
- Power Calculation: 80% power to detect effect size of 0.75
- Alpha: 0.05 (two-sided)
- Assumption: 15% dropout rate
Primary Analysis
The primary efficacy analysis includes:
Between-group comparison: ANCOVA with baseline as covariate
Intention-to-treat: All randomized participants analyzed
Per-protocol: Excluding major protocol violationsSecondary Analyses
Time-by-treatment interaction: Mixed-models repeated measures
Subgroup analyses: By disease severity, age
Correlation analyses: Adherence and outcomes
Effect size estimation: Cohen's d with confidence intervalsSafety Considerations
Contraindications
VR cycling may not be appropriate for individuals with:
History of motion sickness or vestibular disorders
Seizure disorders (flashing lights in VR environments)
Severe visual impairment affecting VR experience
Cardiovascular instability requiring close monitoring
Orthopedic limitations preventing cyclingAdverse Event Monitoring
The study monitored for:
- Falls during cycling sessions
- Musculoskeletal injuries
- Cardiovascular events
- VR-related symptoms (discomfort, nausea)
- Device-related injuries
Safety Protocols
- Initial screening for VR contraindications
- Gradual VR exposure during first sessions
- Close supervision during all sessions
- Immediate access to emergency equipment
- Staff trained in VR-specific safety procedures
Implementation Considerations
Equipment Requirements
Successful VR cycling implementation requires:
Hardware
- VR headset (ideally wireless for safety)
- Stationary bicycle (recumbent preferred for safety)
- Heart rate monitor
- Emergency stop button
Software
- VR cycling applications
- Progress tracking systems
- Safety monitoring features
Environment
- Adequate floor space
- Proper lighting
- Ventilation for exercise
- Clear pathways for emergency exit
Training Requirements
Staff implementing VR cycling should receive:
- VR equipment operation training
- PD-specific exercise knowledge
- Safety protocol training
- Troubleshooting and technical support
- Patient-centered communication skills
Cross-Links
Related Pages
- [Parkinson's Disease - Exercise Therapy](/diseases/parkinsons-disease)
- [Virtual Reality in Neurorehabilitation](/therapeutics/cbs-psp-daily-action-plan)
- [Physical Therapy in Parkinson's Disease](/therapeutics/cbs-psp-daily-action-plan)
- [Clinical Trials in Parkinson's Disease](/clinical-trials/clinical-trials)
- [BDNF and Neuroprotection in PD](/mechanisms/gdnf-signaling-pathway)
Comparative Analysis with Other VR Exercise Trials
Active VR Rehabilitation Trials in PD
| Trial | N | VR Type | Comparison | Phase | Status |
|-------|---|--------|-----------|-------|--------|
| VCYCLE | 40 | Cycling | Standard exercise | Phase 2 | Completed |
| VR-BALANCE | 60 | Balance | Standard PT | Phase 2 | Recruiting |
| VR-GAIT | 50 | Gait training | Treadmill | Phase 1 | Completed |
| HOME-VR | 100 | Home-based | Waitlist | Phase 3 | Active |
Systematic reviews suggest:
- [Motor Function**: Moderate effect size (d = 0.55) for VR vs.](/genes/nct) standard therapy
- Balance: Large effect size (d = 0.78) for VR-added approaches
- Quality of Life: Small-to-moderate effect (d = 0.35)
- Adherence: VR interventions show 20-40% better retention
Comparison of Exercise Modalities
| Modality | Motor Benefit | Cognitive Benefit | Adherence | Accessibility |
|---------|--------------|------------------|-----------|----------------|
| VR Cycling | +++ | ++ | +++ | ++ |
| Standard Cycling | ++ | + | ++ | +++ |
| Treadmill | ++ | + | ++ | +++ |
| Dance (LSVT) | +++ | ++ | ++ | ++ |
| Boxing | +++ | + | ++ | + |
Biomarker Studies
BDNF Response to VR Exercise
The trial includes biomarker substudies examining:
Peripheral BDNF: Blood collection pre/post exercise
Inflammatory Markers: IL-6, TNF-α, CRP
Oxidative Stress: 8-OHdG, malondialdehyde
Growth Factors: IGF-1, VEGFExpected Biomarker Changes
| Marker | VR-Cycling | Standard Cycling | Expected Direction |
|-------|------------|------------------|-------------------|
| BDNF | ↑ 20-40% | ↑ 15-25% | Increased |
| IL-6 | ↓ 10-20% | ↓ 5-15% | Decreased |
| CRP | ↓ 15-25% | ↓ 10-15% | Decreased |
| 8-OHdG | ↓ 10-20% | ↓ 5-10% | Decreased |
Regulatory Pathway
FDA Considerations
VR-based medical devices fall under:
Device Classification: Class II medical device
510(k) Pathway: For cleared VR systems
De Novo Pathway: For novel VR rehabilitation
Device Labeling: Specific indications for PDInsurance Coverage
Current coverage status:
- Medicare: Limited VR coverage for rehabilitation
- Private Insurance: Varies by plan
- Self-Pay: Common for VR rehabilitation
- Veterans Affairs: Coverage through VA hospitals
Reimbursement Codes
| Code | Description | Rate |
|------|-------------|------|
| 97014 | Therapeutic activities | $35-50/session |
| 97016 | Aquatic therapy | $40-55/session |
| 97110 | Therapeutic exercise | $30-45/session |
| 97150 | Manual therapy | $40-60/session |
Implementation Science
Barriers to Implementation
Equipment Costs: VR headsets ($400-1000), bikes ($500-3000)
Training: Staff need specialized training
Space Requirements: Dedicated area needed
Technical Support: IT support may be needed
Patient Familiarity: Learning curve for technologyFacilitators of Adoption
Clinical Evidence: Strong trial results drive adoption
Reimbursement: Adequate payment for services
Training Programs: Comprehensive staff education
Technical Support: Vendor support contracts
Patient Demand: Patient preference drives adoptionScale-Up Considerations
For widespread implementation:
Home-Based VR: Potential for remote supervision
Telehealth Integration: Hybrid VR-telehealth models
Group Sessions: Cost reduction through grouping
Equipment Sharing: Community equipment libraries
Insurance Partnerships: Reimbursement optimizationPatient-Centered Outcomes
Quality of Life Impact
VCYCLE assessed multiple QoL domains:
Physical Function: ADL performance, mobility
Emotional Well-Being: Depression, anxiety, self-efficacy
Social Function: Participation, relationships
Cognitive Function: Memory, attention, processingCaregiver Perspectives
Caregiver burden was monitored:
Time Commitment: Session attendance
Transportation: Travel to facility
Emotional Support: Motivation and encouragement
Safety Monitoring: Supervision requirementsPatient Satisfaction
Satisfaction surveys captured:
Enjoyment: VR experience rating
Motivation: Intrinsic motivation assessment
Perceived Benefit: Subjective improvement
Recommendation: Would recommend to othersFuture Directions
Phase 3 Trial Design
If Phase 2 is successful:
Sample Size: N = 200-300 per arm
Multi-Site: 15-20 sites nationally
Longer Duration: 6-12 month intervention
Follow-Up: 12-month open-label follow-up
Home-Based: Hybrid home/facility designCombination Approaches
Future trials may combine:
VR + Pharmacological: With dopaminergic agents
VR + DBS: With deep brain stimulation
VR + Stem Cells: With cell-based therapies
VR + Gene Therapy: With AAV-based treatmentsPersonalized Rehabilitation
Future directions include:
Biomarker Selection: Based on genetic markers
Severity Stratification: By disease stage
Comorbidity Adjustment: Tailored protocols
Home vs. Facility: Individualized settingExternal Resources
- [ClinicalTrials.gov NCT04804202](https://clinicaltrials.gov/study/NCT04804202)
- [Parkinson's Foundation Exercise Guidelines](https://www.parkinson.org/)
- [VR Rehabilitation in Neurological Conditions](https://pubmed.ncbi.nlm.nih.gov/)
Clinical Outcome Measures Details
MDS-UPDRS Part III Scoring
The motor examination includes:
- Facial Expression: 0-4 scale
- Speech: 0-4 scale
- Rest Tremor: 0-4 for each limb
- Action Tremor: 0-4 for each limb
- Rigidity: 0-4 for each region
- Finger Taps: 0-4 bilaterally
- Hand Movements: 0-4 bilaterally
- Pronation-Supination: 0-4 bilaterally
- Leg Agility: 0-4 bilaterally
- Arising from Chair: 0-4
- Gait: 0-4
- Freezing: 0-4
- Postural Stability: 0-4
- Posture: 0-4
- Global Spontaneity: 0-4
Total score: 0-132, higher = more impairment
Berg Balance Scale Items
Sitting to standing
Standing unsupported
Sitting unsupported
Standing to sitting
Transfers
Standing with eyes closed
Standing with feet together
Tandem standing
Single-leg stance
Turning to look behind
Turning 360 degrees
Step stools
Stepping forward
Lateral steppingTotal: 0-56, higher = better balance
Health Economics
Cost-Effectiveness Analysis
The trial includes health economic evaluation:
Cost per QALY: Quality-adjusted life year calculation
Intervention Costs: Equipment, staffing, overhead
Healthcare Utilization: Hospitalizations, visits avoided
Productivity: Caregiver/work impactBudget Impact Analysis
Estimated annual budget impact if implemented:
- Initial Investment: $50,000-100,000 for equipment
- Per-Patient Cost: $500-1000 for 12-week program
- Break-Even: 50-100 patients annually
- Long-Term Savings: Reduced nursing home placement
Regulatory Pathway
FDA Considerations
VR-based medical devices fall under:
Device Classification: Class II medical device
510(k) Pathway: For cleared VR systems
De Novo Pathway: For novel VR rehabilitation
Device Labeling: Specific indications for PDInsurance Coverage
Current coverage status:
- Medicare: Limited VR coverage for rehabilitation
- Private Insurance: Varies by plan
- Self-Pay: Common for VR rehabilitation
- Veterans Affairs: Coverage through VA hospitals
References
[NCT04804202 - VCYCLE](https://clinicaltrials.gov/study/NCT04804202)
[Shen and Mak, VR Exercise in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35678234/)
[Urs et al., Exercise and PD - Mechanisms of Neuroprotection (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)
[PD Exercise Guidelines (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Albert et al., VR Cycling in PD (2020)](https://pubmed.ncbi.nlm.nih.gov/32878621/)
[Shapkin et al., Aerobic exercise and BDNF in PD (2021)](https://pubmed.ncbi.nlm.nih.gov/34210923/)
[Schulman et al., Immersive VR for PD rehabilitation (2023)](https://pubmed.ncbi.nlm.nih.gov/36785432/)
[Cakit et al., Cycling and motor learning in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35038574/)